TSVT

Insider Trades

Name	Value	Action	Price	Current Price
Baird William D IIIDirector, Officer: President And CEO $25k5.1k shares SellMar 17, 2025 $4.95 --
Eatwell VictoriaChief Financial Officer $13k2.6k shares SellMar 17, 2025 $4.95 --
Snow JessicaChief Operating Officer $11k2.3k shares SellMar 17, 2025 $4.95 --
Kynam Global Healthcare Master Fund, LP10 Percent Owner $25M5.1M shares SellMar 11, 2025 $4.93 --
Snow JessicaSee Remarks $491186 shares SellJan 7, 2025 $2.64 --
Baird William D IIIDirector, Officer: President And CEO $2.1k763 shares SellJan 6, 2025 $2.78 --

Trade TSVT

About 2seventy bio, Inc.

2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company. Founded in 2021, its corporate headquarters are situated in Cambridge, Massachusetts.

CEO: William D. Baird III,
IPO Date: Nov 3, 2021

Market Data

Open: $5.00
High: $5.00
Low: $5.00
Volume: 1.2M
Avg Volume: 1.5M
52W High: $5.30
52W Low: $2.29

Valuation

Market Cap: $266M
Enterprise Value: $414M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-86M
Revenue: $38M
Net Income: $-57M
Cash: $71M
Debt: $244M

Events

EarningsNov 10